Cyclic pyranopterin monophosphate regulatory update

Alexion said FDA granted breakthrough therapy designation for ALXN1101 to treat molybdenum cofactor deficiency (MoCD) Type A, a rare genetic disorder characterized by severe brain damage and rapid dea...